Showing results (121-130 of 190) with videos related to
Sort By:
Pageof 19
Cancer Research|August 2, 2014
Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemiaBenjamin Werner, Robert E Gallagher, Elisabeth M Paietta, et al.The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.Leukemia & Lymphoma|November 25, 2011
Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)Peter H Wiernik, Hailun Li, Edie Weller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's LymphomaThomas E Witzig, Peter H Wiernik, Timothy Moore, et al.Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.British Journal of Haematology|February 28, 2009
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaThomas M Habermann, Izidore S Lossos, Glen Justice, et al.Molecular Cancer Therapeutics|April 17, 2012
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemiaJeremy B Samon, Mireia Castillo-Martin, Michael Hadler, et al.Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.Blood|September 27, 2003
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupJacob M Rowe, Donna Neuberg, William Friedenberg, et al.Pageof 19